Thursday, May 12, 2022 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Many organizations have yet to figure out how to fit digital, hybrid, and decentralized clinical trial methods into their existing ecosystems in a scalable and efficient way. This webinar will go through the complexities that decentralized and hybrid methodologies bring to first-generation platforms, and how a single, unified platform enables interoperability and flexibility to help truly unlock the potential of these digital study methods.
Decentralized and hybrid clinical trials changed from a futuristic possibility to a reality overnight. While it has taken time for the industry to digest this fundamental shift, research shows that these new methodologies are here to stay.
Many organizations have yet to figure out how to fit these new methods into their existing ecosystems in a scalable and efficient way. Current eClinical platforms natively lack key digital data capture capabilities, which then necessitates complex third-party integrations, resulting in data redundancy and quality issues.
This webinar will go through the complexities that decentralized and hybrid methodologies bring to first-generation platforms, and how a single, unified platform enables interoperability and flexibility to help truly unlock the potential of these digital study methods.
Key Learning Objectives:
Who Should Attend:
Director, Life Sciences Product Strategy
Oracle Health Sciences
Tony is a product Strategist with over 20 years of experience in the pharmaceutical and healthcare industries. He has a Master of Business Administration from The University of Texas at San Antonio. With a broad range of experience in Data Management across Biotech, Pharma and CRO, he has also spent time implementing an MDR solution within numerous research organizations. He is looking to focus his experience to foster advances in the Data Collection space and thereby improve the Clinical Development Lifecycle.
Executive Director Digital Trials Strategy
Oracle Health Sciences
As Oracle’s Executive Director Digital Trials Strategy, David Blackman has responsibility for aligning digital strategies and innovations with Oracle’s developing business needs. Within his role in Oracle’s Health Sciences Global Businesses Unit, David is responsible for creating and developing differentiating technology and business capabilities through development, partnerships and acquisitions that enhance clinical trial research and accelerate bringing drugs to market for our clients.
Before joining Oracle in 2021, he served in the Corporate Development and Strategy group at PPD where he had responsibility for PPDs business innovation, leading and incubated cutting-edge business solutions resulting in the investment, development, integration and commercialization of digital and remote clinical trials capabilities. Prior to that David worked at IBM/Lenovo, where he held a number of global technology and business leadership roles.
A graduate of the University of Johannesburg in South Africa, he combines his more than 20 years of technological experience in development, process and technology innovations with his commitment to implementing cutting-edge technologies as a platform that advance innovative technology solutions in clinical trials worldwide. He holds two patents for technology innovations in human factors.